- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
An open-label, multicenter Phase 1/2 dose escalation and expansion study of THOR-707 as a single agent and as a combination therapy in adult subjects with advanced or metastatic solid tumors
This study is testing a new medicine, THOR-707, for people with advanced cancer. It aims to find the safest and most effective dose, and see how well it works alone or with other treatments to shrink tumours and improve health.
For: CancerSpain - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
This study is looking at a new medicine for people in the UK with Hodgkin Lymphoma that has come back or hasn't responded to other treatments. It aims to check if the new medicine, AZD7789, is safe, what effects it has, and if it helps in treating the cancer.
For: Relapsed/Refractory Classical Hodgkin LymphomaItaly · Denmark · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An open-label, first-in-human, dose-escalation/expansion study of SAR443579 administered as single agent by intravenous infusion in adult and pediatric participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)
This study is testing a new medicine called SAR443579 for adults and children with certain types of blood cancers that haven't responded to other treatments. It aims to find the right dose and see how well it works and if it's safe.
For: Acute lymphocytic leukaemia- Acute myeloid leukaemia refractory - Myelodysplastic syndrome - Blastic plasmacytoid dendritic cell neoplasiaFrance · Netherlands - Active not recruitingPHASE3
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
This study is looking at a new way to give a medicine called isatuximab for a type of blood cancer called multiple myeloma. It compares giving the medicine as a shot under the skin versus through a drip into a vein, always with other standard treatments.
For: Plasma Cell Myeloma RecurrentUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A PHASE 2 MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN SUBJECTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA (INHL)
This study looks at a new type of cell therapy, Yescarta, for people with certain types of slow-growing non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. Researchers are checking how well it works and if it's safe over many years.
For: Follicular Lymphoma · Marginal Zone Lymphoma · Indolent Non-Hodgkin LymphomaFrance - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
An Open-label, Randomized Phase Ib/II Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma
This study is for people in the UK with multiple myeloma that has come back or not responded to previous treatments. It investigates new combinations of medications, including one called Forimtamig, to see how safe and effective they are.
For: Multiple myeloma (MM)Spain · Denmark · France - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2a, Open-label, Dose Escalation Trial of GEN3017 with Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma
This study is testing a new medicine called GEN3017 for people with Hodgkin or non-Hodgkin lymphoma. It's an early-stage trial looking at safe doses and checking for side effects, as well as seeing how well the treatment shrinks the cancer.
For: Hodgkin lymphoma or non-Hodgkin lymphomaGermany · Denmark · Italy - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI 1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
This study is testing a new drug, BI 1910, for people with advanced cancers. It will check how safe the drug is, what side effects it causes, and how much of it the body can handle, both on its own and when given with another cancer drug.
For: Advanced solid tumorsDenmark · Poland · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA-3745 in participants with glycogen storage disease type 1a (GSD1a), followed by an open-label extension
This study is testing a new medicine, mRNA-3745, for Glycogen Storage Disease Type 1a (GSD1a). It's looking at how safe it is, how well people tolerate it, and how it works in the body, starting with low doses and gradually increasing them.
For: Glycogen storage disease type 1a (GSD1a)Spain · Poland · Netherlands - AuthorisedTherapeutic exploratory (Phase II)
A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma
This study looks at a new type of cell therapy, called MB-CART2019.1, for people with a specific type of lymphoma that has come back or hasn't responded to other treatments. It checks how safe and effective it is.
For: Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL)Hungary · Croatia - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of mRNA 3210 in Participants with Phenylketonuria
This study is testing a new messenger RNA (mRNA) medicine called mRNA-3210 for people with Phenylketonuria (PKU). Researchers want to see if it's safe, how much of it stays in the body, and how it affects PKU. It's an early-stage study, meaning it's one of the first times it's being given to humans.
For: Participants with PhenylketonuriaFrance · Spain · Italy - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
This study is looking at a new medicine called obinutuzumab for people with a serious kidney problem called lupus nephritis. Researchers want to see if it's safe and helps better than a dummy medicine when added to usual treatments, like steroids.
For: Lupus NephritisUnited States · Argentina · Brazil